Latest news
- BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
14:00 - GlobeNewswire - Yemeni Houthis threaten to continue attacks on SA
13:31 - TeleTrader - JBS USA and Pilgrim’s to Provide COVID-19 Vaccine for 8,500 Essential Team Members in Multiple Locations
12:00 - GlobeNewswire - British finances can't be fixed 'overnight' - Sunak
11:59 - TeleTrader - HK Police: 47 activists charged for subversion
10:43 - TeleTrader
Real-time